Psychotropic agents and uses thereof

Abstract

Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or a2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or α2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of dopamine and/or serotonin in the brain, either individually or in combination with other CNS active agents.

1 . A compound having a structure of Formula I: 
       
         
           
           
               
               
           
         
         including pharmaceutically acceptable salts and stereoisomers thereof, wherein:
 R 1  is 
 
       
       
         
           
           
               
               
           
         
         
            and 
           X and Z are the same or different and independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroarylalkyl, and heteroaryl, optionally the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroarylalkyl, and heteroaryl groups are further substituted with one or more substitution groups selected from the group consisting of halogens such as chlorine, bromine and fluorine, amines, hydroxy groups, carboxylic acids, nitro groups, carbonyl and other alkyl and aryl groups as defined herein; with the proviso that at least one of X and Z is not hydrogen. 
         
       
     
     
         2 . The compound of  claim 1 , wherein the compound is a stereoisomer having a structure of Formula I-S: 
       
         
           
           
               
               
           
         
         including pharmaceutically acceptable salts thereof. 
       
     
     
         3 . The compound of  claim 1 , wherein R 1  is 
       
         
           
           
               
               
           
         
       
     
     
         4 . The compound of  claim 1 , wherein R 1  is 
       
         
           
           
               
               
           
         
       
     
     
         5 . The compound of  claim 1   4 , wherein X and Z are the same or different and independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, and heteroaryl, optionally the alkyl, alkenyl, alkynyl, aryl, and heteroaryl groups are further substituted with one or more substitution groups selected from the group consisting of halogens such as chlorine, bromine and fluorine, amines, hydroxy groups, carboxylic acids, nitro groups, carbonyl and other alkyl and aryl groups as defined herein; with the proviso that at least one of X and Z is not hydrogen. 
     
     
         6 . The compound of  claim 1 , wherein X is H. 
     
     
         7 . The compound of  claim 6 , wherein X═H and Z═CH 3 . 
     
     
         8 . A pharmaceutical composition comprising a compound of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         9 . A method of delivering into the brain of a subject a dopamine and/or serotonin and/or α2 receptor antagonist comprising administering to the subject a therapeutically effective amount of the compound of  claim 1 , wherein the level of the dopamine and/or serotonin and/or α2 receptor antagonist in brain is higher than the level of amisulpride when amisulpride is administered to the subject at a comparable dose. 
     
     
         10 . A method of antagonizing dopamine and/or serotonin and/or α 2  receptor in a subject comprising administering to the subject a therapeutically effective amount of the compound of  claim 1 , either individually or in combination with other CNS active agents. 
     
     
         11 . A method of treating one or more conditions responsive to modulation of dopamine and/or serotonin and/or α 2  receptor in a subject comprising administering to the subject a therapeutically effective amount of the compound of  claim 1 , either individually or in combination with other CNS active agents. 
     
     
         12 . A method of treating one or more disorders associated with an abnormality in levels of dopamine and/or serotonin in the brain of a subject, the method comprising administering to the subject a therapeutically effective amount of the compound of  claim 1 . 
     
     
         13 . The method of  claim 11 , wherein the disorder or condition is a mental illness. 
     
     
         14 . The method of  claim 13 , wherein the mental illness is schizophrenia. 
     
     
         15 . The method of  claim 10 , wherein the method further comprising administering to the subject a therapeutically effective amount of another medication. 
     
     
         16 . The method of  claim 10 , wherein the disorder or condition is selected from the group consisting of depression, bipolar disorder, Tourette's syndrome, Schizoaffective disorder, Parkinson's psychosis, Alzheimer's psychosis, oppositional defiant disorder, childhood schizophrenia, dysthymia, treatment resistant schizophrenia, chronic fatigue syndrome, and predominantly negative symptoms of schizophrenia. 
     
     
         17 - 26 . (canceled) 
     
     
         27 . The method of  claim 10 , wherein the serotonin receptor is 5-HT 2a  receptor. 
     
     
         28 . The method of  claim 10 , wherein the α2 receptor is selected from the group consisting of α2A receptor, α2B receptor, α2C receptor, and combinations thereof. 
     
     
         29 - 30 . (canceled)